Health · 27 views
New T-cell engager shows promise for advanced solid tumors
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors.
Summary
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell engager (TCER) that specifically links cancer cells with T cells, thereby directly activating the immune system to fight the tumor. To achieve this, the molecule simultaneously binds to two targets: a protein produced in tumor cells known as the tumor antigen MAGEA4/8, and a molecule on the surface of the body's immune cells (CD3).
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- I’m a psychoanalyst. Social media is damaging children’s inner lives in ways we don’t fully understand | Robin KirmanContinue reading
- Just 3 minutes with miniature horses and donkeys improves mood of teensContinue reading
- Exercise — and echocardiograms — in space protected astronauts’ hearts in studyContinue reading
- Rising Healthcare Costs Have Hit Georgia’s Most Conservative District. But Its Politics Are Unlikely To Change.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow